Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TFAM siRNA
- Development stage
- Preclinical
- Lead developer
- University of Southern California
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
TFAM siRNA is a small interfering RNA designed to silence the expression of Transcription Factor A, Mitochondrial (TFAM). TFAM is a key regulator of mitochondrial DNA transcription and replication, and its overexpression has been linked to metabolic plasticity and cisplatin resistance in bladder cancer. By knocking down TFAM, the siRNA reduces the population of aggressive, stem-like, drug-resistant side population (SP) cells and depletes mitochondrial DNA. This intervention has been shown to synergize with cisplatin treatment in bladder cancer cell lines, potentially overcoming non-mutation-mediated chemoresistance.
- Other names
- Transcription Factor A, Mitochondrial siRNAmitochondrial transcription factor A siRNA
02
Targets
Transcription factor A, mitochondrial mRNA
Beyond the preview
Go deeper on TFAM siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TFAM siRNA.